More recently, antidiabetic medications, such as SGLT2 inhibitors, have demonstrated benefit in the treatment of heart failure in non-diabetic patients, resulting in a level 1A recommendation for their use in heart failure irrespective of diabetic status[4]. Here, SLC5A2 is linked to heart failure.